Arbutus Biopharma
ABUS
ABUS
111 hedge funds and large institutions have $215M invested in Arbutus Biopharma in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 7 closing their positions.
Holders
111
Holders Change
+12
Holders Change %
+12.12%
% of All Funds
1.63%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
20
Increased
34
Reduced
29
Closed
7
Calls
$4.66M
Puts
$3.94M
Net Calls
+$719K
Net Calls Change
+$64K
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$34.9M |
| 2 |
WCM
2
Whitefort Capital Management
New York
|
$33M |
| 3 |
TSC
3
Two Seas Capital
Rye,
New York
|
$22.6M |
| 4 |
CC
4
Centiva Capital
New York
|
$3.55M |
| 5 |
5
State Street
Boston,
Massachusetts
|
$5.99M |
Top Sellers
| 1 |
FCM
1
FourWorld Capital Management
New York
|
$2.73M |
| 2 |
JFG
2
Jefferies Financial Group
New York
|
$0 |
| 3 |
KC
3
Kepos Capital
New York
|
$0 |
| 4 |
4
Citigroup
New York
|
$53.2K |
| 5 |
5
Citadel Advisors
Miami,
Florida
|
$4.83M |
